EP2066646A1 - Process for the preparation of pure anastrozole - Google Patents
Process for the preparation of pure anastrozoleInfo
- Publication number
- EP2066646A1 EP2066646A1 EP07824193A EP07824193A EP2066646A1 EP 2066646 A1 EP2066646 A1 EP 2066646A1 EP 07824193 A EP07824193 A EP 07824193A EP 07824193 A EP07824193 A EP 07824193A EP 2066646 A1 EP2066646 A1 EP 2066646A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- organic solvent
- process according
- anastrozole
- solvent used
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Definitions
- the present invention relates to an improved process for preparing pure anastrozole. Moreover the process relates to alkylation of the isolated and purified 3,5-bis(2-cyanoprop- 2-yl)benzylbromide as starting material, without the use of toxic, hazardous and environmentally unfriendly solvents.
- Anastrozole is a common name for the chemically known substance 2,2'-[5-(1H-1 ,2,4- triazol-1-ylmethyl)-1 ,3-phenylene]di(2-methylpropionitrile), represented by formula (I) :
- Anastrozole is a selective and potent non-steroidal drug which inhibits the action of the enzyme aromatase. It is used for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Anastrozole is further recognized and granted for treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown, locally advanced or metastatic breast cancer and also for adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. The synthesis of anastrpzole is described in U.S. Pat. Nos. 4935437 and RE 36617 ( a reissue of U.S. Pat. No.4935437 assigned to AstraZeneca Pharmaceuticals).
- the starting material 3,5-bis(bromomethyl)-toluene
- potassium cyanide in dichloromethane in the presence of a catalytic amount of tetrabutylammonium bromide (TBAB) to obtain 2,2'-(5-methyl-1 ,3-phenylene)diacetonitrile.
- TBAB tetrabutylammonium bromide
- the product is mixed with iodomethane and sodium hydride in DMF to thereby obtain 2,2'- (5-methyl-1 ,3-phenylene)di(2-methylpropionitrile), (also referred to as 3,5-bis(2-cyanoprop- 2-yl)toluene) which is further brominated using benzoyl peroxide and N-bromosuccinimide (NBS) in carbon tetrachloride.
- NBS N-bromosuccinimide
- the mixture is refluxed for 2 hours, cooled, filtered, and the filtrate is evaporated to dryness under reduced pressure.
- the residue obtained is dissolved in DMF and sodium triazole is added.
- anastrozole is purified by flash column chromatography, eluting with ethyl acetate. The last part of this process is shown in Scheme 1 below.
- the bromomethyl intermediate in the process is not isolated or purified in either process, but is directly converted to anastrozole in situ.
- an impure final product is obtained.
- US 20060189670 describes the preparation of anastrazole by reacting 3,5 bis-(1-cyano-1 methyl ethyl)benzylhalide with 4-Z-1 ,2,4-triazole.
- US 2006/0035950 provides processes (scheme II) for purifying anastrozole, avoiding the use of liquid chromatography.
- the purification processes are via the isolated anastrozole salt forms, either by crystallization or by selective acidic extractions, and optionally in both cases, converting the purified anastrozole salt to anastrozole base.
- a process for the synthesis of anastrozole, which is obtained by alkylating the isolated, purified, 3,5-bis(2- cyanoprop-2-yl)benzylbromide is also disclosed.
- the above patent describes the preparation of 3,5-bis(2-cyanoprop ⁇ 2-yl)benzylbromide, which is carried out in a solvent of either dichloromethane (the yield is low), or acetonitrile (the yield is not reported) and purified (the yield reported in this process is low).
- steps involved in the synthesis of anastrozole resulting in lower yield. For example, following alkylation to produce crude anastrozole, the US'950 process involves converting the crude anastrozole to a salt of anastrozole, isolating the salt of anastrozole, optionally recrystallising the salt of anastrozole, optionally converting the salt of anastrozole to anastrozole base and isolating the product.
- the bromination reaction as described in '950 can be carried out in a solvent selected from the group of ethyl acetate, acetone, dichloromethane, methyl acetate, isopropyl acetate, isopropyl acetoacetate, tert-butyl acetate and acetonitrile.
- a solvent selected from the group of ethyl acetate, acetone, dichloromethane, methyl acetate, isopropyl acetate, isopropyl acetoacetate, tert-butyl acetate and acetonitrile.
- the impurity 3,5- bis(cyanoprop-2-yl)benzyl bromide, a compound of formula (IV) formed during the reaction was found to an extent of 15-20% and other problems were encountered using some of these solvents which are susceptible to bromination.
- the main object of the present invention is to provide an improved process for preparation of anastrazole with purity greater than 99.8%.
- the present invention provides a process for the preparation of anastrozole which comprises:
- the bromination reaction of step a) is carried out at the reflux temperature of the solvent used in step a). It has surprisingly been found that carrying out the refluxing for a period of time not longer than 3 hours reduces the formation of the impurity 3, 5- bis(cyanoprop-2-yl)benzyl bromide (IV)
- a process for the preparation of anastrozole which comprises: a) brominating 3,5-bis(2-cyanoprop-2- yl)toluene (II) in an organic solvent using a brominating agent to obtain 3,5-bis(2- cyanoprop-2-yl)benzylbromide (III); b) heating the reaction mass of step a) to the reflux temperature of the organic solvent for a period of time no longer than 3 hours; c) isolating and purifying the bromo intermediate (III) using an organic solvent; d) alkylating the bromo intermediate in the presence of a base, optionally a phase transfer catalyst, a 1,2,4-triazole and an organic solvent to obtain anastrozole; e) isolating and purifying the anastrozole from an organic solvent.
- the organic solvent in the brominating step is acetonitrile.
- the organic solvent in the brominating step is acetonitrile.
- the refluxing is carried out for 3 hours.
- the refluxing is carried out for 1 hour.
- the preferred the organic solvent for use in step a) is acetonitrile. It has surprisingly been found that using acetonitrile as the bromination solvent is particularly effective in aiding the removal of the impurity (IV).
- a process for the preparation of anastrozole which comprises: a) brominating 3,5 ⁇ bis(2-cyanoprop-2- yl)toluene (II) in acetonitrile using a brominating agent to obtain 3,5-bis(2-cyanoprop-2- yl)benzylbromide (III); b) isolating and purifying the bromo intermediate (III) using an organic solvent;c) alkylating the bromo intermediate in the presence of a base, optionally a phase transfer catalyst, a 1 ,2,4-triazole and an organic solvent to obtain anastrozole; and d) isolating and purifying the anastrozole from an organic solvent.
- the bromination reaction mass is heated to the reflux temperature of the organic solvent for a period of time no longer than 3 hours.
- acetonitrile as the organic solvent in the brominating step and employing the step of heating the bromination reaction mass to the reflux temperature of the organic solvent for a period of time no longer than 3 hours is particularly preferred.
- the brominating agent may be an N-halosuccinimide.
- the N-halosuccinimide is N-bromosuccinimide.
- the organic solvent used in the purification of the brominated intermediate may be selected from the group consisting of isopropyl alcohol, n-heptane, n-hexane, toluene and mixtures thereof.
- the organic solvent is a mixture of isopropyl alcohol and n- heptane.
- the isolation of the brominated intermediate may involve quenching the reaction mass with water, concentrating the quenched reaction mass to a residue, charging an organic solvent such as methylene chloride to the residue, filtering the insolubles and washing with the solvent.
- the organic layer may be washed with a sodium sulfite solution, followed by a sodium chloride solution then a sodium chloride solution.
- the layer may then be washed with water, dried and concentrated to a residue.
- the base used in the alkylating step may be selected from the group consisting of potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate and mixtures thereof.
- the base is potassium carbonate and potassium hydroxide, and the potassium hydroxide is in powdered form.
- the phase transfer catalyst may be a quaternary ammonium salt for example a tetraalkyl ammonium halide, or a crown ether.
- the alkyl group is an alkyl of 1 to 18 carbon atoms.
- the alkyl is methyl, ethyl or propyl.
- the halide may be chloro, bromo or iodo.
- the tetraalkyl ammonium halide may be Me 4 NCI, Me 4 NBr, Me 4 NI, Et 4 NBr, n- PfyNCI, n-P ⁇ NI or n-Bu 4 NBr.
- the tetraalkyl ammonium halide is tetrabutylammonium bromide.
- the organic solvent used in the alkylating step may be selected from the group consisting of toluene, DMF, acetonitrile and cyclohexane.
- the organic solvent is toluene.
- the 1 ,2,4-triazole is 1 ,2,4-triazole or a salt thereof, for example an alkali metal salt.
- the 1 ,2,4-triazole is the sodium salt of 1 ,2,4-triazole.
- the organic solvent used in the step of purifying anastrozole may be a water immiscible solvent or a mixture of water immiscible solvents. Surprisingly, it has been found that a mixture of ethylacetate and diisopropylether is particularly preferred for the isolation and purification of anastrozole. This combination of solvents is particularly effective in aiding the removal of impurities, especially those formed during the bromination step.
- a process for the preparation of anastrozole which comprises: a) brominating 3,5-bis(2-cyanoprop-2- yl)toluene (II) in an organic solvent using a brominating agent to obtain 3,5-bis(2- cyanoprop-2-yI)benzylbromide (III); b) isolating and purifying the bromo intermediate (III) using an organic solvent; c) alkylating the bromo intermediate in the presence of a base, optionally a phase transfer catalyst, a 1,2,4-triazole and an organic solvent to obtain anastrozole; d) isolating and purifying the anastrozole from ethylacetate and diisopropylether.
- the organic solvent in the brominating step is acetonitrile.
- the bromination reaction mass is heated to the reflux temperature of the organic solvent for a period of time no longer than 3 hours.
- a process for purifying crude anastrozole comprising crystallising anastrozole from ethylacetate and diisopropylether.
- the ethylacetate and diisopropylether are charged to the crude anastrozole, the mixture is optionally stirred for example for a period of time ranging from 10 minutes to 1 hour, suitably for around 30 minutes, chilling the mixture for example to a temperature ranging from about 0 to about 10 0 C, suitably from about 0 to about 5°C, and isolating the solid product, for example by filtration, washing and drying under vacuum.
- none of the organic solvents used in any of the steps is carbon tetrachloride.
- benzoyl peroxide is present in the bromination step.
- an acid is present in the bromination step.
- the acid may be sulphuric acid or acetic acid.
- the acid is sulphuric acid.
- the refluxing of the bromination reaction mass may be carried out in a shorter time, for example in one hour. This shorter time is particularly preferred as it aids in reducing the formation of impurity (IV).
- a particularly preferred embodiment of the process for the preparation of anastrozole according to the present invention is one in which the organic solvent used in the brominating step is acetonitrile, the bromination reaction mass is heated to the reflux temperature of the organic solvent for a period of time no longer than 3 hours, the brominating agent is N-bromosuccinimide, an acid is optionally present during the bromination step, the organic solvent used in the purification of the brominated intermediate is a mixture of isopropyl alcohol and n-heptane, the organic solvent used in the alkylation step is toluene and the organic solvent used in the purification of anastrozole is a mixture of ethylacetate and diisopropylether.
- the purified product of the bromination reaction contains the impurity 3,5-bis(cyanoprop-2-yl)benzyl bromide (IV) in an amount ranging from 5 to 8%.
- the purified product of step b) is substantially free from the impurity 3, 5-bis(cyanoprop-2-yl)benzyl bromide (IV)
- the anastrozole prepared according to the process of the present invention may be obtained with purity greater than or equal to 99.8%. Typically, the anastrozole is obtained with purity of 99.8%. Desirably, the anastrozole is obtained with purity of 99.8%.
- Anastrozole prepared according to the process of the present invention forms another aspect of the present invention.
- anastrazole having a purity greater than or equal to 99.8%.
- the anastrozole has a purity of 99.8%.
- the anastrozole has a purity of 99.9%.
- the process of the present invention is as shown in scheme III.
- the starting material 3,5-bis(2-cyanoprop-2-yl)toluene is brominated using N- bromosucccinimide (NBS) to the benzyl bromide intermediate 3,5-bis(2-cyanoprop-2- yl)benzylbromide (formula III) in the presence of benzoyl peroxide in acetonitrile.
- NBS N- bromosucccinimide
- the bromination reaction is carried out at reflux temperature for not more than 3 hours after which time the impurity 3,5-bis(cyanoprop-2-yl)benzylbromide, a compound of formula (IV), is formed in a substantially low percentage.
- impurity (IV) is formed in an amount ranging from about 5 to 8 %.
- impurity (IV) is formed to an extent ranging from about 40 to 50% because of the solvent used and the longer reaction time.
- the small amount of the impurity of formula (IV) generated in the bromination step is efficiently removed by purifying the bromo intermediate using a suitable solvent, which results in 3,5-bis(cyanoprop-2-yl)benzyl bromide with purity greater than 90%.
- the suitable solvent used for purifying the bromo compound is an organic solvent and may be selected from the group consisting of isopropyl alcohol, n-heptane, n-hexane, toluene and mixtures thereof.
- a particularly preferred solvent is a mixture of isopropyl alcohol and n-heptane.
- the purified bromo compound (formula (III)) is alkylated with 1 ,2,4-triazole in a suitable solvent using a suitable base in the presence of a phase transfer catalyst such as tetrabutyl ammonium bromide to obtain anastrozole, which is further purified using column chromatography, followed by precipitation/crystallization using ethyl acetate and diisopropyl ether to obtain pure anastrozole in high yield.
- a phase transfer catalyst such as tetrabutyl ammonium bromide
- Suitable solvents used for the above alkylation reaction are selected from the group consisting of toluene, DMF, acetonitrile and cyclohexane, preferably toluene.
- Suitable bases used are selected from the group consisting of potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate and mixtures thereof, preferably potassium carbonate and powdered potassium hydroxide. 5
- the process of the present invention affords anastrozole in high yield and high purity, the purity of the pure anastrozole obtained may be measured by HPLC.
- the anastrozole prepared by the present invention has purity greater than or equal to 10 99.8%. In particular, anastrozole prepared by the present invention may have purity of 99.9%.
- Acetonitrile(1300 ml), 3,5-bis(2-cyanoprop-2-yl) toluene (100 g), benzoyl peroxide (2.3 g) and acetic acid (1.2 ml) were heated to 50-55 0 C.
- N-bromosuccinimide (100 g) was added over a period of 3 hours, maintained for 30 minutes, then the temperature was slowly raised to reflux (75-8O 0 C) and maintained for 3 hours. After reaction completion, the mass was cooled to 25-3O 0 C, water (2.5 ml) was added and concentrated under vacuum to residue at a temperature lower than 6O 0 C.
- the toluene layer was concentrated under vacuum to residue at 50-55 0 C, isopropyl alcohol (18.8 ml) was charged followed by n-heptane (450 ml), the contents were stirred for 1 hour at 25-3O 0 C, the contents were chilled to 0-5 0 C, maintained for 45 minutes, and the resulting material was filtered and washed with n-heptane (25 ml).
- the above material was loaded on a Silica gel column, eluted with methylene chloride followed by the polarity being increased (to an extent of 30%) using ethyl acetate.
- the pure fractions containing anastrozole were concentrated to residue at 40-45 0 C, cooled to 20-25 0 C, methanol (420 ml) was charged, stirred for dissolution, clarified over hyflo and concentrated to residue under vacuum at 40-45 0 C.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1719MU2006 | 2006-10-17 | ||
PCT/GB2007/003942 WO2008047104A1 (en) | 2006-10-17 | 2007-10-17 | Process for the preparation of pure anastrozole |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2066646A1 true EP2066646A1 (en) | 2009-06-10 |
EP2066646B1 EP2066646B1 (en) | 2012-06-13 |
Family
ID=38951273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07824193A Ceased EP2066646B1 (en) | 2006-10-17 | 2007-10-17 | Process for the preparation of pure anastrozole |
Country Status (4)
Country | Link |
---|---|
US (1) | US7989636B2 (en) |
EP (1) | EP2066646B1 (en) |
KR (1) | KR101502322B1 (en) |
WO (1) | WO2008047104A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1751121A2 (en) | 2005-04-06 | 2007-02-14 | Sicor Inc. | Process for the preparation of anastrozole |
EP2066646B1 (en) | 2006-10-17 | 2012-06-13 | Cipla Limited | Process for the preparation of pure anastrozole |
EP2343278A1 (en) | 2010-01-07 | 2011-07-13 | Hexal AG | A process for preparing trisubstituted phenyl derivatives comprising a (1H-1,2,4-triazol-1-yl)alkyl group |
ITRM20130285A1 (en) | 2013-05-14 | 2014-11-15 | Corden Pharma Latina S P A Con Uni Co Socio | METHOD FOR THE PREPARATION OF PHARMACEUTICAL GRADE ANASTROZOL |
CN103554041B (en) * | 2013-11-12 | 2016-02-03 | 江苏正大清江制药有限公司 | A kind of synthesis technique preparing Anastrozole |
BR102021016123A2 (en) | 2021-08-16 | 2023-02-23 | Petróleo Brasileiro S.A. - Petrobras | PROCESS FOR BIODIESEL PRODUCTION FROM ACID CARDS |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8714013D0 (en) * | 1987-06-16 | 1987-07-22 | Ici Plc | (substituted-aralkyl)heterocyclic compounds |
US20060035950A1 (en) | 2004-08-09 | 2006-02-16 | Mohammed Alnabari | Novel processes for preparing substantially pure anastrozole |
US20060189670A1 (en) | 2005-02-22 | 2006-08-24 | Glenmark Pharmaceuticals Limited | Process for the preparation of anastrozole and intermediates thereof |
EP1705168A1 (en) * | 2005-03-21 | 2006-09-27 | Helm AG | Improved process for side-chain bromination of alkyl-benzenes |
EP1751121A2 (en) * | 2005-04-06 | 2007-02-14 | Sicor Inc. | Process for the preparation of anastrozole |
US20090286989A1 (en) * | 2006-03-10 | 2009-11-19 | Vishnukant B | Process for High Purity Anastrozole |
EP2066646B1 (en) | 2006-10-17 | 2012-06-13 | Cipla Limited | Process for the preparation of pure anastrozole |
-
2007
- 2007-10-17 EP EP07824193A patent/EP2066646B1/en not_active Ceased
- 2007-10-17 KR KR1020097009967A patent/KR101502322B1/en not_active IP Right Cessation
- 2007-10-17 US US12/444,613 patent/US7989636B2/en not_active Expired - Fee Related
- 2007-10-17 WO PCT/GB2007/003942 patent/WO2008047104A1/en active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of WO2008047104A1 * |
Also Published As
Publication number | Publication date |
---|---|
US7989636B2 (en) | 2011-08-02 |
KR101502322B1 (en) | 2015-03-13 |
WO2008047104A1 (en) | 2008-04-24 |
US20100099887A1 (en) | 2010-04-22 |
EP2066646B1 (en) | 2012-06-13 |
KR20090085062A (en) | 2009-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060035950A1 (en) | Novel processes for preparing substantially pure anastrozole | |
US7705159B2 (en) | Process for the preparation of letrozole | |
EP2066646B1 (en) | Process for the preparation of pure anastrozole | |
US6559316B2 (en) | Method for preparing 2-(2-hydroxyphenyl)-2H-benzotriazole | |
US7692025B2 (en) | Process for the preparation of anticancer drugs | |
US20080207915A1 (en) | Process for the Preparation of 2,2'-[5-(1H-1,2,4-Triazole-1-Ylmethyl) -1,3-Phenylene] Di (2-Methylpropionitrile) | |
US7465749B2 (en) | Letrozole purification process | |
US8003804B2 (en) | Synthesis of 4-[1-(4-cyano phenyl)-(1,2,4-triazol-1-yl)methyl] benzonitrile and 4-[1-(1H-1,2,4-triazol-1-yl)methylene benzonitrile intermediate | |
JP2004506043A (en) | Method for producing cilostazol | |
US20050209294A1 (en) | Process for producing 4-(1H-1,2,4-triazol-1-ylmethyl)benzonitrile | |
US20080177081A1 (en) | Process for Preparation of Anastrozole | |
US20090221837A1 (en) | Process for the Preparation of Pure Anastrozole | |
WO2007039912A1 (en) | A one pot process for the preparation of 4-[1-cyanophenyl)-1-(1,2,4-triazol-1-yl)methyl]benzonitrile | |
KR100973616B1 (en) | Method for the production of 1,2,4-triazolylmethyl-oxiranes | |
CN103554041B (en) | A kind of synthesis technique preparing Anastrozole | |
EP2456758B1 (en) | A process for preparing trisubstituted phenyl derivatives comprising a (1h-1,2,4-triazol-1-yl)alkyl group | |
CN104387332A (en) | Method for synthesizing aromatase inhibitor | |
CN118255753A (en) | Synthesis method of olmesartan medoxomil intermediate | |
WO2009010991A2 (en) | Purification process to prepare highly pure anastrozole | |
PL204392B1 (en) | Method of obtaining 2,2'-(5-(1H-1,2,4-triazol-1-)-ylmethyl)-1,3-phenylene)di(2-methylpropionitrile) | |
MX2007002740A (en) | Improved process for the preparation of letrozole | |
JPS58216166A (en) | Production of n-substituted imidazole | |
KR20080112306A (en) | Synthesis of 4-[1-(4-cyano phenyl)-1-(1,2,4-triazol-1-yl)methyl] benzonitrile and 4-[1-(1h-1,2,4-triazol-1-yl)methylene benzonitrile intermediate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090320 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
RBV | Designated contracting states (corrected) |
Designated state(s): GB GR TR |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: 8566 |
|
17Q | First examination report despatched |
Effective date: 20100409 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): GB GR TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120914 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20121017 Year of fee payment: 6 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20130314 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120613 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20131017 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20131017 |